The Risk of Arterial Thrombosis in Patients With Chronic Myeloid Leukemia Treated With Second and Third Generation BCR-ABL Tyrosine Kinase Inhibitors May Be Explained by Their Impact on Endothelial Cells: An In-Vitro Study

BCR-ABL tyrosine kinase inhibitors (TKIs) revolutionized the treatment of chronic myeloid leukemia, inducing deep molecular responses, largely improving patient survival and rendering treatment-free remission possible. However, three of the five BCR-ABL TKIs, dasatinib, nilotinib, and ponatinib, inc...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Front Pharmacol
Glavni autori: Haguet, Hélène, Bouvy, Céline, Delvigne, Anne-Sophie, Modaffari, Elise, Wannez, Adeline, Sonveaux, Pierre, Dogné, Jean-Michel, Douxfils, Jonathan
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2020
Teme:
Pharmacology
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7350860/
https://ncbi.nlm.nih.gov/pubmed/32719607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2020.01007
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items